Overview A Study to Evaluate ABT-126 for the Treatment of Cognitive Deficits in Schizophrenia Status: Completed Trial end date: 2014-07-01 Target enrollment: Participant gender: Summary This is a safety and efficacy study evaluating a experimental treatment for cognitive deficits in adults with schizophrenia. Phase: Phase 2 Details Lead Sponsor: AbbVie (prior sponsor, Abbott)